PAH News

September 20, 2018September 20, 2018

Adempas Seen to Benefit Idiopathic PAH Patients Who Fail to Respond to Revatio in Pilot Study

News, PAH News

Idiopathic pulmonary arterial hypertension (IPAH) patients who failed to respond to treatment with Revatio (sildenafil), either alone or combined with other phosphodiesterase type 5 inhibitors, may benefit by switching to Adempas (riociguat), according to ... Read more

September 19, 2018September 19, 2018

Actelion’s Opsumit Shows Promise as Treatment for Portopulmonary Hypertension, Trial Results Show

News, PAH News, PH News

Actelion Pharmaceuticals’ Opsumit (macitentan) may be a potential therapy for portopulmonary hypertension, according to positive results from a Phase 4 clinical study. The data was presented at the European Respiratory Society ... Read more

September 13, 2018September 13, 2018

Researchers Pinpoint Protein that Contributes to Blood Vessel Changes in PAH

News, PAH News

A protein called RAGE was found to be an important contributor to the remodeling of blood vessels in pulmonary arterial hypertension (PAH). This is an important finding because it could ... Read more

September 12, 2018September 12, 2018

Pregnancy is High-Risk Mortality Factor Among PAH Women, ROPAC Study Reveals

News, PAH News

Pregnancy among women with heart diseases is generally safe, with just a few deaths being reported in the ROPAC registry during a 10-year period. However, pregnancy was found to ... Read more

September 7, 2018September 11, 2018

PhaseBio Obtains $34M in Financing to Advance Therapies for PAH, Other Diseases

News, PAH News

PhaseBio Pharmaceuticals has secured $34 million in Series D financing to advance the clinical development of PB1046, an investigational therapy for pulmonary arterial hypertension (PAH), as well as its lead ... Read more

September 6, 2018September 6, 2018

United Therapeutics and MannKind Team Up to Advance Pulmonary Hypertension Therapy

News, PAH News

United Therapeutics and MannKind established a worldwide exclusive licensing and agreement to develop and commercialize a dry powder formulation of treprostinil, an approved vasodilator, for pulmonary arterial hypertension (PAH) ... Read more

August 30, 2018September 3, 2018

Investigational Extended-Release Ralinepag for PAH Treatment Shows Favorable Results in Phase 1 Trials

News, PAH News

Extended-release tablets of ralinepag, Arena Pharmaceuticals’ treatment candidate for pulmonary arterial hypertension (PAH), show a superior pharmacokinetic profile over both immediate-release ralinepeg capsules and approved immediate-release medication Uptravi (selexipag), according ... Read more

August 27, 2018August 30, 2018

Higher Concentration of Inhaled Ventavis May Help PAH Patients Stick to Treatment, Study Suggests

News, PAH News

More pulmonary arterial hypertension (PAH) patients were able to achieve complete daily inhalations after switching to a more concentrated formulation of Ventavis (iloprost), which also reduced the duration of each treatment ... Read more

August 24, 2018August 28, 2018

Research Study Identifies Two Proteins as Potential Biomarkers of SSc-PAH

News, PAH News, Scleroderma

Evaluation of Midkine (MDK) and Follistatin-like 3 (FSTL3) protein levels in the blood can help identify patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH), researchers suggest. The study, “Serum ... Read more

August 22, 2018August 24, 2018

Mylan Announces U.S. Launch of 20 mg Tadalafil Tablets, 1st Generic of Adcirca for PAH Treatment

News, PAH News

Mylan recently introduced a formulation of 20 mg tadalafil tablets, the first generic version of Eli Lilly‘s Adcirca, in the United States for patients with pulmonary arterial hypertension (PAH). The ... Read more

Pin It on Pinterest